Liquid Biopsy for Early Detection of Colorectal Cancer
This study is looking for a better way to find colorectal cancer (CRC) early. Researchers are testing a "liquid biopsy" called a cf-circRNA assay. This test looks for special circular RNAs (cf-circRNAs) in your blood (plasma or serum) that might show if you have CRC. You could join if you are an adult (18 or older) with confirmed Stage I-III colorectal cancer and have blood samples available from before your treatment. The main goal is to see how well this test can find CRC (its "sensitivity"). This is an observational study, meaning researchers will collect information without giving new treatments, and it plans to include 600 participants. The study status is currently unclear.
- Study design
- This is an observational study planning to enroll 600 participants to test a diagnostic method.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, sensitivity, is measured through study completion, an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ajay Goel, PhD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- SensitivityThrough study completion, an average of 1 year
Proportion of early-stage (Stage I-II) colorectal cancer patients correctly identified as positive by the circRNA-based diagnostic model.